APD-Capped Cationic Peptoids for Stable mRNA Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Therapeutic nucleic acids face challenges such as rapid degradation, poor cellular uptake, and inefficient endosomal escape, leading to suboptimal expression and immune response concerns in traditional delivery systems.
Innovation Solution
Development of 2-aminopropane-1,3-diol-capped cationic peptoids as a tunable ionizable lipid component in delivery vehicles, optimized through DOE methodology to form complexes with polyanionic compounds like mRNA, enhancing expression and reducing immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If traditional delivery systems (viral vectors, cationic lipid nanoparticles, polycationic polymers) are used for nucleic acid delivery, then cellular uptake and delivery capability are improved, but stability, toxicity, and immune response worsen
Solution Approach 1:
The patent modifies the chemical structure of lipid components by incorporating 2-aminopropane-1,3-diol (APD) moieties with specific pKa values (6.0-7.5), hydrophobic chain lengths (C12-C22), and headgroup compositions to optimize the balance between cellular uptake efficiency and reduced toxicity/immune response. This parameter optimization allows the delivery system to maintain effective cellular interaction while minimizing harmful effects.
2Productivity
If cationic lipid nanoparticles are used for nucleic acid delivery, then delivery efficiency is improved, but stability and rapid clearance worsen
Solution Approach 1:
The patent creates composite lipid nanoparticle systems combining ionizable lipids with 2-aminopropane-1,3-diol moieties, phospholipids, cholesterol, and PEGylated lipids in specific ratios. This composite structure provides both efficient nucleic acid delivery and enhanced stability in circulation, preventing rapid clearance while maintaining delivery effectiveness.
3Ease of operation
If polycationic polymers are used for nucleic acid delivery, then cellular uptake is improved, but endosomal escape efficiency worsens
Solution Approach 1:
The patent utilizes the pH-dependent phase transition properties of ionizable lipids with 2-aminopropane-1,3-diol moieties. These lipids remain neutral at physiological pH for stable circulation and cellular uptake, then undergo phase transition to become cationic in the acidic endosomal environment, enabling effective endosomal membrane disruption and cargo release.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The peptoid-based delivery vehicles achieve a >10,000-fold increase in mRNA expression in vivo with minimal tolerability concerns, demonstrating stability and low toxicity, suitable for therapeutic applications.
Implementation Method 1
The delivery vehicle compositions of the disclosure can form an electrostatic interaction between the 2-aminopropane-1,3-diol-capped cationic peptoids of the delivery vehicle composition and a polyanionic compound, such as a nucleic acid
Data Source
AI summary
The present disclosure provides delivery vehicle compositions comprising hydroxyalkyl-capped cationic peptoids, such as 2-aminopropane-1,3-diol-capped cationic peptoids, and complexes of the delivery vehicles with polyanionic compounds, such as nucleic acids. The disclosure further provides methods of making and using the delivery vehicle compositions and complexes, such as for the delivery polyanionic compounds (e.g., nucleic acids) to cells. The disclosure also provides methods of eliciting an immune response with the delivery vehicle complexes of the disclosure.